← Leaderboards
Moanaro Biswas
Indiana University Indianapolis
$1,334,592
Attributed
$1,334,592
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $582.6K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,334,592 · 3
By mechanism
R33$582,638 · 1
R21$451,980 · 1
R56$299,974 · 1
Top collaborators
No co-investigators on record.
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Roland W. Herzog$25,146,618
- Weidong Xiao$16,949,600
- Marco C Bottino$5,644,127
- Thomas D. Hurley$11,294,425
- Randal J. Kaufman$37,816,764
Others in their field
Other Rising Stars on “Hemophilia A”
- Paris Margaritis · Geneventiv Therapeutics, Inc.$2,542,236
- Christian Kastrup · Versiti Wisconsin, Inc.$2,182,730
- Sasha H Bakhru · Perosphere Technologies Inc.$1,966,607
- Sewoon Han · Cellfe Inc.$1,680,456
- Benjamin Richard Hawley · Engage Biologics Inc.$865,162
- Seema Rajnikant Patel · Emory University$705,303
Research focus
Hemophilia AEngineeringProliferatingTransplantationAutoimmune DiseasesDoseDesignPharmaceutical PreparationsReceptor SignalingReplacement TherapyInterleukin-2Regulatory T-LymphocyteAntibodiesClinical TranslationAntibody FormationAntibody ResponseBiological Response Modifier TherapyBlood Coagulation FactorInnovationChimeric Antigen ReceptorImmune ResponseImmunosuppressionAutoimmunityCd3 Antigens
Grant awards (4)
Immunocytokine therapy for immune modulation in hemophilia$582,638
R33 · FY2025 · HL · contact PI
Optimizing precision Treg therapy to control anti-drug antibodies$299,974
R56 · FY2024 · AI · contact PI
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics$239,768
R21 · FY2024 · HL · contact PI
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics$212,212
R21 · FY2023 · HL · contact PI